Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accumulated Depreciation (2020 - 2023)

Historic Accumulated Depreciation for Relay Therapeutics (RLAY) over the last 4 years, with Q4 2023 value amounting to $23.6 million.

  • Relay Therapeutics' Accumulated Depreciation rose 2823.97% to $23.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $23.6 million, marking a year-over-year increase of 2823.97%. This contributed to the annual value of $23.6 million for FY2023, which is 2823.97% up from last year.
  • According to the latest figures from Q4 2023, Relay Therapeutics' Accumulated Depreciation is $23.6 million, which was up 2823.97% from $18.4 million recorded in Q4 2022.
  • Over the past 5 years, Relay Therapeutics' Accumulated Depreciation peaked at $23.6 million during Q4 2023, and registered a low of $10.5 million during Q4 2020.
  • Over the past 4 years, Relay Therapeutics' median Accumulated Depreciation value was $16.4 million (recorded in 2021), while the average stood at $16.7 million.
  • In the last 5 years, Relay Therapeutics' Accumulated Depreciation surged by 3643.87% in 2021 and then surged by 2799.47% in 2022.
  • Relay Therapeutics' Accumulated Depreciation (Quarter) stood at $10.5 million in 2020, then skyrocketed by 36.44% to $14.4 million in 2021, then rose by 27.99% to $18.4 million in 2022, then rose by 28.24% to $23.6 million in 2023.
  • Its last three reported values are $23.6 million in Q4 2023, $18.4 million for Q4 2022, and $14.4 million during Q4 2021.